Use of Chitosan Powder in Loop Electrosurgical Excision Procedure
Vaginal Bleeding, Loop Electrosurgical Excision
About this trial
This is an interventional prevention trial for Vaginal Bleeding
Eligibility Criteria
Inclusion Criteria: women were aged > 21 years old women were not pregnant women who were undergoing LEEP. Exclusion Criteria: Women with pelvic infection Women with abnormal vaginal bleeding Women with coagulopathy Women with chronic pain syndromes Women with psychiatric disorders Women with the previous hysterectomy with removal of the cervix, Women with a history of cervical cancer Women who could not complete follow-up calls
Sites / Locations
- Kemal GüngördükRecruiting
- Mugla Sıtkı Kocman University Education and Research Hospital
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control
Chitosan
LEEP was performed in an outpatient setting by a single resident physician (KG). A full blood count was taken (hematocrit 1). The procedure was designed according to colposcopic findings such as the type of transformation zone and position of the lesion. After positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) was applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix. LEEP was performed as described in a previous trial. After the hemostasis that obtained using the ball electrode at a 40-W coagulation setting, the remaining cervical tissue was washed with 20 ccs of sterile saline to ensure no active bleeding from the cervical wound. An empty spray pump was used because we cannot find any identical powder for the placebo
LEEP was performed in an outpatient setting by a single resident physician (KG). A full blood count was taken (hematocrit 1). The procedure was designed according to colposcopic findings such as the type of transformation zone and position of the lesion. After positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) was applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix. LEEP was performed as described in a previous trial. After the hemostasis that obtained using the ball electrode at a 40-W coagulation setting, the remaining cervical tissue was washed with 20 ccs of sterile saline to ensure no active bleeding from the cervical wound. The application of 3 or 4 pumps of chitosan powder was carried out into the wound bed by spray pump which was prepared by a nurse.